Over the past few years, there have been several key developments in the Treatment Resistant Depression Market. Development of new drugs: The pharmaceutical industry has been investing heavily in the development of new drugs for TRD. Several new drugs have been introduced in the market, including esketamine (Spravato), brexanolone (Zulresso), and ketamine. These drugs work differently from traditional antidepressants and have shown promising results in clinical trials. Increasing use of electroconvulsive therapy (ECT): ECT is a form of therapy that involves passing an electric current through the brain to induce a seizure. It is used to treat severe depression that does not respond to medication or psychotherapy. Over the past few years, there has been an increase in the use of ECT for TRD, as it has been shown to be effective in some patients.
Read more @ https://creativeedge16.blogspot.com/2023/04/treatment-resistant-depression-market.html
Sign in to leave a comment.